Biometric Stock Research Update: NXT-ID, Inc. (OTCQB: NXTD) Increasing Intrinsic Value (IV) Estimate After Company Completes New Accretive Financing Round

BOSTON, MA - January 28, 2014 (Investorideas.com Newswire) SoundView Technology Group: NXT-ID (OTCQB: NXTD) www.nxt-id.com has effectively raised an additional round of capital that will come in two tranches -- $1.35M less expenses up front and another $4.4M from likely warrant exercises. The proceeds will aid the company in further development and the commercial launch of their innovative digital wallet (The Wocket www.thewocket.com).

In an unusually shareholder-friendly move founding members of the management team elected to surrender shares to offset the additional shares need for new investment capital. Few, if any, company managements go to such lengths to put shareholders first.
Thanks to this decision an adjustment to our intrinsic valuation (IV) model results in an increase from $10.93 (published in December 2013) and our new IV estimate of $11.51.
Market forces continue to favor adoption of digital wallet technologies and NXT-ID is certainly one of the leading contenders for what will be a commercial market in 2014.
Our full note is available for download here.
About SoundView Technology Group
We are an independent advisory and research firm specializing in emerging technologies as they reach commercialization. Our proprietary research and modeling work provides valuable information for company management teams and investors in these emerging opportunities. We regularly publish our findings across a variety of channels including all the major retail and institutional information outlets. SoundView is based in Boston, Massachusetts with locations in New York and Connecticut.
Disclosures
SoundView does provide paid advisory services NXT-ID on their business plans, technology description and investor positioning. However SoundView analysts do not receive compensation for their research opinions, any specific views or conclusions. They are tasked to provide fact-based research with clear analysis. SoundView does not provide investment advice or make "buy/sell/hold" recommendations. Nor do we provide investment banking or brokerage services. We act as a publisher of our own research work and are responsible for all content which is correct to the best of our abilities but by no means should it be relied upon without further validation and confirmation.
Contact:
Kirin Smith
Director of Research
SoundView Technology Group
617-828-6462
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: November 2013 :Investorideas is compensated by NXTD: five thousand per month for news publication and syndication and is long 144 shares from previous services
More info: http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Power Generation Stock Research: Powerdyne International, Inc. (PWDY) Announces Analyst Report From Murphy Analytics, LLC

WARWICK, RI - January 28, 2014 (Investorideas.com renewable energy stocks newswire) Powerdyne International, Inc. (OTC:PWDY), a manufacturing company that builds and leases electrical generation equipment, today announced that Murphy Analytics LLC, a prominent small cap research boutique led by Patrick J. Murphy has commenced research coverage of Powerdyne International, Inc. The analyst report is available here: www.powerdyneinternational.com

The report highlights the fact that energy consumption will continue to increase (28% in electricity consumption from 2012 to 2040 according to the Energy Information Administration), and there are "significant opportunity for alternative sources of electricity generation" such as those manufactured by Powerdyne International, Inc.
The report states:
As a manufacturer of portable, scalable electricity generators powered by natural gas (as well as other fuels), PWDY is targeting a market in which large scale economic trends are creating significant opportunity for alternative sources of electricity generation to be consumed by a wide range of potential municipal, industrial and commercial clients
About Powerdyne International, Inc.:
Powerdyne International, Inc. is a manufacturing company that builds and leases electrical generation equipment including its own portable electrical power generation equipment called PDIGenset (which is patent and trademark pending).
PDIGensets are designed to be installed at virtually any location. The genset is leased and maintained by PDI. Although the company's target customer will typically use its PDIGenset to produce its own primary electrical power, it can be used for emergency back-up power generation and is useful in any situation where reliable power is needed.
PDI is founded on the ability to produce primary electrical power using proprietary technology to power electrical generation equipment which makes electricity cheaper than existing means of producing primary electric power. PDI expects that the difference between its cost of generating electricity over its customer's current cost will result in substantial savings to the customer.
For more information on Powerdyne International go to: www.PowerdyneInternational.com
This release may contain "forward-looking statements" that are within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect the Company's current expectations about its future plans and performance, including statements concerning the impact of marketing strategies, new product introductions and innovation, deliveries of product, sales, earnings and margins. These forward-looking statements rely on a number of assumptions and estimates which could be inaccurate and which are subject to risks and uncertainties. Actual results could vary materially from those anticipated or expressed in any forward-looking statement made by the Company. Please refer to the Company's most recent Form 10-K and subsequent filings with the Securities and Exchange Commission for a further discussion of these risks and uncertainties. The Company disclaims any obligation or intent to update the forward-looking statements in order to reflect events or circumstances after the date of this release.
Contact:
Powerdyne International, Inc.
contact@powerdyne.org
More from the Report:
Powerdyne International, Inc. – January 22, 2014
PWDY Products Target Opportunity Created by a Convergence of Fundamental U.S. Economic Market
Dynamics
Select Stock Trading Data
Recent Stock Price $0.0126
Shares Outstanding: 195.42 million
Float 28.77 million
Recent Market Cap: $2.46 million
52 Week Range: $.007 - $0.20
Exchange: OTCBB
Ticker: PWDY
URL: http://www.powerdyneinternational.com/
Data sourced from Yahoo! Finance; otcbb.com; Company filings
Powerdyne International, Inc is a development stage manufacturing company that builds and leases electrical generation equipment including its own portable electrical power generation equipment called PDIGenset (which is patent trademark pending). PDIGensets are designed to be installed at virtually any location. The genset is leased and maintained by PDI. Although the company's target customer will typically use its PDIGenset to produce its own primary electrical power, the genset is designed to be useful in any situation where reliable power is needed. PDI is founded with the objective to produce primary electrical power using proprietary technology to power electrical generation equipment which makes electricity cheaper than existing means of producing primary electric power. PDI expects that the difference between its cost of generating electricity over its customer's current cost will result in substantial savings to the customer.
PWDY's initial product is the PDIGenset (patent pending) which is a self-contained generator that is powered by a modified radial air cooled engine to drive a minimum of a 1-megawatt generator. The entire unit, which runs on natural gas or propane, is compact, lightweight and clean burning. As a result, the unit will produce extremely low emissions and is designed to be extremely energy-efficient. PWDY has recently completed a fully operational factory Series 2 prototype, which has been tested and is ready as a demonstration unit. This unit is available for any prospective customers to view in full operational capacity. In addition, the Series 2 prototype is ready to be manufactured for customers upon placement of customer orders.
PWDY plans to manufacture, install, maintain and lease its own portable electrical power equipment. The Company plans to manufacture portable electrical power equipment intended to be installed at client locations. The Company will own, maintain and lease the equipment to the customer who will use it to produce its own supplemental electrical power. The Company's products are intended to be portable, easy-to-use units that can be conveniently redeployed in various locations around the world. The Company's units can also be assembled and combined to produce power centers providing up to 50 megawatts of power. The Company's headquarters are located in Warwick, Rhode Island and operates a manufacturing facility in Massachusetts. The Company will market its products in locations where inexpensive electrical power is needed and clean energy powered electrical equipment is needed and/or required.
As forecast in the U.S. Energy Information Administration's (EIA) recently released Annual Energy Outlooki, factors such as economic structural changes, higher electricity prices, mandated environmentally friendly standards, and improved efficiencies are expected to slow the rate of growth in electricity consumption. However, from 2012 to 2040, the EIA still expects an increase of 28% in electricity use which is forecast to grow from 1.8% of GDP currently to 2.4% of GDP in 2040.
While it seems reasonable to expect that electricity demand will create market opportunity for PWDY products, it's also important to consider what may happen to price and demand for the fuels that power those products. The following conclusions from the EIA report address the outlook for natural gas in particular:

• "Growing domestic production of natural gas and oil continues to reshape the U.S. energy economy...
• With continued growth in shale gas production, natural gas becomes the largest source of U.S. electric power generation, surpassing coal by 2035, and boosting production and natural gas consumption in manufacturing.
• Strong growth in domestic natural gas production supports increased exports of both pipeline and liquefied natural gas. With strong growth in domestic oil and gas production, U.S. dependence on imported fuels falls sharply..."

While an increase in the use of, and demand for, natural gas for electricity generation, transportation and industrial uses would seem to imply that prices must increase, the EIA cites massive expected increases in shale gas production as a driver for keeping prices low. With 2012 U.S. dry natural gas production estimated at approximately 25 trillion cubic feet in 2012, the EIA expects U.S. production to surpass 100 trillion cubic feet by 2040, with shale gas accounting for approximately half of that production resulting in modest expected increases in natural gas prices enabling the U.S. to remain a net exporter of petroleum products.
With both increasing electricity demand and stable fuel prices as positive macro trends for PWDY products, the Company also is targeting a market in which changing fundamentals create opportunity as well. As characterized by David Crane, CEO of NRG Energy (NYSE: NRG), which generates 47,000 megawatts from solar, wind, fossil and nuclear sources - enough to support almost 40 million homes, changes in power production and consumption driven by distributed generation in particular represent "a mortal threat to the existing utility system."
Read the full report and disclaimers and disclosures at http://www.powerdyneinternational.com/files/pdf/pr/pwdy_1-22-2014.pdf
Investorideas.com Disclaimer/ Disclosure : The Investorideas.com newswire is a recognized news source and publisher of news and research. Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news release submissions, content marketing and online advertising. All investment involves risk. More info: http://www.investorideas.com/About/Disclaimer.asp

Disclosure: Investorideas has been compensated by PWDY two thousand for news publication and content publishing for one month.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors please refer to your regulation regarding trading foreign securities.

Wall Street’s Greatest Security and Defense Conference This Year; Cybersecurity and Counterterrorism Analyst Roger Cressey of Liberty Group Ventures Added

New York, N.Y. - January 24, 2014 (www.investorideas.com newswire) Defense and Security News alert- Investorideas.com, an investor research and news portal covering leading sectors including technology and defense, announces new speakers for its upcoming Security and Defense Conference,” Game Changing Technologies: The Face and Future of Security”, to be held live in New York and online at Scribblelive.com on March 11, 2014.

Added to the growing list of speakers and presenters is Kris Tuttle Director of Research for SoundView Technology Group, cybersecurity expert and counterterrorism analyst Roger Cressey, Partner with Liberty Group Ventures and Kiersten Todt , President and Managing Partner of Liberty Group Ventures.
The theme of the conference is game changing technologies, changing the face and the future of security, discussing technologies and developments in biometrics including fingerprint, voice and facial recognition, biodefense, cyber security as well as other leading edge technology. Current presenting companies include innovative biometric company NXT- ID Inc. and itsMobileBio™ suite of technologies and Tekcapital, Ltd., “The World's Largest University Network for Open Innovation.”
Roger Cressey is a Partner with Liberty Group Ventures, LLC in Arlington VA, a risk and crisis management firm specializing in cyber security, campus security and sports security. He most recently served as a Senior Vice President at Booz Allen Hamilton, supporting the firm's cyber security practice in the Middle East. Prior to joining Booz Allen, he was President and Founder of Good Harbor Consulting LLC, a security and risk management consulting firm.
Mr. Cressey's government service included senior cyber security and counterterrorism positions in the Clinton and Bush Administrations. At the White House, he served as Chief of Staff of the President's Critical Infrastructure Protection Board from November 2001 - September 2002. He also served as Deputy for Counterterrorism on the National Security Council staff from November 1999 to November 2001. He was responsible for the coordination and implementation of US counterterrorism policy and managed the US Government response to multiple terrorism incidents, including the Millennium terror alert, the USS COLE attack, and the September 11th attacks.
From 2004 - 2013, he served as an on-air counterterrorism analyst with NBC News, appearing frequently on NBC Nightly News, The Today Show, MSNBC and CNBC.
Prior to his White House service, Mr. Cressey served in the Department of Defense, where he worked on US defense strategy and the review of Pentagon war plans. From 1991-1995, he served in the Department of State working on Middle East security issues, including serving as a member of the US delegation to the multilateral track of the Arab-Israeli peace process talks.
More info: http://www.investorideas.com/Conference/Speakers.asp
Kiersten Todt is the President and Managing Partner of Liberty Group Ventures, LLC (LGV). She develops risk and crisis management solutions for infrastructure, emergency management, cybersecurity, higher education, and homeland security clients in the public, private, and non-profit sectors. She has served in senior positions in both the executive and legislative branches of government. Ms. Todt has commented on homeland security and sport security issues in multiple media outlets, including MSNBC, NPR, Bloomberg, and The Wall Street Journal. Her work on sport security has been published in two editions of The International Centre for Sport Security Journal.
More info: http://www.investorideas.com/Conference/Speakers.asp
Kris Tuttle is the Director of Research for SoundView Technology Group which focuses on researching and analyzing emerging public companies in new technology areas. Kris has 35 years of active participation in computing technologies including as an early designer and programmer of microcomputers, a researcher building artificial intelligence applications at Carnegie Mellon University and a career at IBM applying a range of advanced technologies to the most challenging business applications faced by Fortune 500 companies.
Starting in 1992 he has been applying this background to technology stock investing. After the original SoundView was acquired, ultimately by UBS and Charles Schwab, he founded his own firm in 2005 and renamed it SoundView after re-acquiring the SoundView trademarks. Today the firm is focused on advisory services, research and developing more internet-based research and information services.
More info: http://www.investorideas.com/Conference/Speakers.asp
Additional speakers include Marty Martin, CEO of Crane & Crane Consulting, who also has a background with the CIA, NSA, and the U.S. Army, Scott Greiper, President and Founding Partner of Secure Strategy Group, Scott Sacknoff, President of Spade Defense Index (NYSE: ^DXS) .
More info: http://www.investorideas.com/Conference/Speakers.asp
Presenting Companies
NXT- ID Inc. - Mobile Security for a Mobile World
NXT-ID, Inc.'s innovative MobileBio™ solution mitigates consumer risks associated with mobile computing, m-commerce and smart OS-enabled devices. The company is focused on the growing m-commerce market, launching its innovative MobileBio™ suite of biometric solutions that secure consumers' mobile platforms led by the Wocket™, a next generation smart wallet designed to replace all the cards in your wallet, no smart phone required. The Wocket works anywhere credit cards are accepted and only works with your biometric stamp of approval. http://www.thewocket.com/
NXT-ID' wholly owned subsidiary, 3D-ID LLC, is engaged in biometric identification has 22 licensed patents in the field of 3D facial recognition http://www.nxt-id.com/, http://3d-id.net/
Tekcapital, Ltd. - The World's Largest University Network for Open Innovation. Tekcapital helps clients profit from new, university-developed intellectual properties. With our proprietary discovery search engine, linked to 3,300+ universities in 160 countries, coupled with expert scientific review, we provide a turn-key service to make it easy for clients to find and acquire the IP they need to create a competitive advantage. http://tekcapital.com/
Investorideas.com Security and Defense Conference:
Game Changing Technologies: The Face and Future of Security
Tuesday, March 11, 2014
The New York Hilton Midtown and Online at Scribblelive.com, a unique content and syndication platform
Learn more about the conference and register:
http://www.investorideas.com/Conference
On March 11, 2014 Hear Industry Analysts, Industry Experts and Management of Leading Companies Discuss How Technology is Transforming the Future of Security

• Over 15 Presenting Companies and 500 expected attendees
• Commentary From Top Industry Experts, Government Officials and Analysts, Live and Online
• Real Time Live Syndication Platform
• Social Media Interaction
• Extensive Media Coverage

Authentication Technology, Biometrics, Biodefense, Drones, Nanotechnology & Technology is evolving faster than we think!
This one day event (both live and online) will give investors and industry participants insight as to where to invest and the key trends to pay attention to.
Live conference attendance is free for industry experts, investors, media and service providers.
Register: http://www.investorideas.com/Conference/Conference-Registration.asp
Presenting Companies: Visit the conference page to learn more and sign up:
http://www.investorideas.com/Conference
Media Partners and Sponsors:
See a list of our media partners here:
http://www.investorideas.com/Conference/
About InvestorIdeas.com:
InvestorIdeas.com is a global news source for investors following leading business sectors including biotech, tech, mining, mobile, energy, water, defense and security, renewable energy, food and beverage stocks and Latin American stocks.
Sign up for our free news alerts:
http://www.investorideas.com/Resources/Newsletter.asp
Become an Investorideas.com Member and use our online stock directories to research stocks - waters stocks, renewable energy, tech, mobile, mining stocks and more… http://www.investorideas.com/membership
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.aspBC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: Disclosure: NXTD and Tekcapital are clients of Investorideas.com .http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
Presenting Companies Contact info:
Cali V cvanzant@investorideas.com 800. 665. 0411
Sponsorship info:
Eric Salvarezza esalvarezza@investorideas.com 631. 664. 1311
Media Partners:
Dawn V dvanzant@investorideas.com 800. 665. 0411
800-665-0411 - Source: www.Investorideas.com

Investorideas.com Security and Defense Conference adds New Speakers and Media Partners and Presenters

New York, N.Y. - January 22, 2014 (www.investorideas.com newswire) Investorideas.com, an investor research and news portal covering leading sectors including technology and defense, announces new speakers and media partners for its upcoming Security and Defense Conference to be held in New York on March 11, 2014. Added to the growing list of speakers and presenters is Kris Tuttle Director of Research for SoundView Technology Group.

Media partners include SecuritySolutionsWatch.com, a breaking News site covering new security solutions and business trends, SecurityStockWatch.com for investors following the sector, www.Wallstreetcalendar.com , informing the institutional investment community, Australian Security Magazine ( http://www.australiansecuritymagazine.com.au/ ) Global Security Finance (www.globalsecurityfinance.com), an online daily news and data service covering the physical, cyber and identity security and defense sectors, and Hedge Connection ( https://www.hedgeconnection.com ), an interactive, web-based marketing tool available to hedge funds and investors.
Current speakers include Marty Martin, CEO of Crane & Crane Consulting, who also has a background with the CIA, NSA, and the U.S. Army, Scott Greiper, President and Founding Partner of Secure Strategy Group, Scott Sacknoff, President of Spade Defense Index (NYSE: ^DXS) .
The theme of the conference is game changing technologies, changing the face and the future of security.
“According to The Washington Post, biometrics might be the one to watch. In much the same way that 3D printing was an engineering resource that had remained under the radar for some time, biometric technology is one that has gathered more traction over the last few months. "
Source: http://why.knovel.com/all-engineering-news/2908-biometric-technology-could-be-one-to-watch-in-2014.html
Investorideas.com Security and Defense Conference:
Game Changing Technologies: The Face and Future of Security
Tuesday, March 11, 2014
The New York Hilton Midtown and Online at Scribblelive.com, a unique content and syndication platform
Learn more about the conference and register:
http://www.investorideas.com/Conference
On March 11, 2014 Hear Industry Analysts, Industry Experts and Management of Leading Companies Discuss How Technology is Transforming the Future of Security

• Over 15 Presenting Companies and 500 expected attendees
• Commentary From Top Industry Experts, Government Officials and Analysts, Live and Online
• Real Time Live Syndication Platform
• Social Media Interaction
• Extensive Media Coverage

Authentication Technology, Biometrics, Biodefense, Drones, Nanotechnology & Technology is evolving faster than we think!
This one day event (both live and online) will give investors and industry participants insight as to where to invest and the key trends to pay attention to.
Live conference attendance is free for industry experts, investors, media and service providers.
Presenting Speakers:
Kris Tuttle, SoundView Technology Group
Kris Tuttle is the Director of Research for SoundView Technology Group which focuses on researching and analyzing emerging public companies in new technology areas. Kris has 35 years of active participation in computing technologies including as an early designer and programmer of microcomputers, a researcher building artificial intelligence applications at Carnegie Mellon University and a career at IBM applying a range of advanced technologies to the most challenging business applications faced by Fortune 500 companies.
Starting in 1992 he has been applying this background to technology stock investing. After the original SoundView was acquired, ultimately by UBS and Charles Schwab, he founded his own firm in 2005 and renamed it SoundView after re-acquiring the SoundView trademarks. Today the firm is focused on advisory services, research and developing more internet-based research and information services.
Kris has a BS in Applied Math/Computer Science from Carnegie Mellon University and an MBA in Finance from the NYU Stern School of Business.
Marty Martin, CEO, Crane & Crane Consulting
Marty Martin has an accomplished career which includes service with the CIA, NSA, and the U.S. Army. He has developed invaluable insight, managerial experience, and relationships across the U.S. Government and many foreign governments and intelligence services at the highest levels. He is the CEO of Crane & Crane Consulting, LLC where he leads the firm's expansion and growth. He previously served as a Senior Executive for the International Oil Trading Company (IOTC), a multi-billion dollar enterprise with activities in Iraq, Jordan, Libya, Russia and the Caribbean. He also played a central role in HBO's Manhunt, a 2013 Emmy awarding winning documentary. Mr. Martin's experience includes over 29 years of U.S. Government service including U.S. Special Forces, the National Security Agency, and the CIA, culminating in several years as a member of the CIA's Senior Intelligence Service. From 2004 through 2007 he served as Chief of Station in a strategic country in the Middle East in one of the most senior assignments in the Near East Division. He managed a multi-million dollar budget, strategic programs, personnel, and families in high threat environment. His experience includes representing the CIA at the highest levels in foreign countries, the U.S. Executive Branch, the U.S. Congress, U.S. Military, on all intelligence and policy matters concerning the agency's operations. In 2002 he was selected by the Director of Central Intelligence as the senior executive and operational manager to lead the Agency's global effort to neutralize Al-Qaida. In that role, he interacted at the highest levels of the U.S Government, including the White House, FBI, Homeland Security, NSA, Congress, and various branches of the U.S. Military, on a daily basis. During this specific period the lion's share of the perpetrators of 9/11 were nullified.
Scott Greiper, President and Founding Partner of Secure Strategy Group
Mr. Greiper is the President and Founding Partner of Secure Strategy Group. He has had a distinguished 15-year career in the security and defense technology sectors as both a research analyst and investment banker, and is known as a thought leader in the industry. Before forming Secure Strategy Group, he was a Managing Director at Legend Merchant Group and Head of the firm's Convergent Security Group, which provided capital, strategic advisory and M&A services to growth companies in the security and defense technology markets. Previously, Mr. Greiper was a Principal and Senior Analyst at C. E. Unterberg, Towbin, where he covered public companies in the Global Security industry and was consistently ranked as one of the top analysts in the sector. He has worked with a range of industry leaders and is a frequent guest speaker and moderator at conferences and seminars across the country. Mr. Greiper attended the Executive MBA program at Columbia University and holds a B. A. in Economics from The University of Chicago. He is a member of the FBI InfraGard program, BENS (Business Executives for National Security), ASIS (American Society for Industrial Security) and NYSSA (New York Society for Security Analysts).
Scott Sacknoff, President, The Spade Defense Index
Mr. Scott Sacknoff is the Index Manager of the SPADE Defense Index (NYSE: ^DXS), the underlying index for the Powershares Aerospace & Defense ETF (NYSE: PPA). The SPADE® Defense Index (NYSE: ^DXS) is a modified capitalization-weighted index comprised of publicly traded companies that benchmarks the performance of companies involved with defense, homeland security, and space. The Index is composed of more than 50 firms with representative business activities including: naval vessels, military aircraft, missiles and munitions, battlespace awareness, C4ISR, network centric warfare, homeland security including border security and biometric and screening systems, and space systems. Index values are distributed by the NYSEarca under the ticker 'DXS'. The Powershares Aerospace & Defense Portfolio ETF, designed to track the SPADE Defense Index, trades under the ticker 'PPA'. Historical data for the Index is available from 30 December 1997. The ETF was launched on 26 October 2005 and is highly liquid.
Presenting Companies: Visit the conference page to learn more and sign up:
http://www.investorideas.com/Conference
Media:
SecuritySolutionsWatch.com features thought leadership interviews about security solutions. As the #1 Google site for Physical Security Solutions, Secure ID Solutions and Security Stocks our channel delivers an excellent branding and lead generation opportunity for new business + greater investor awareness.
About InvestorIdeas.com:
InvestorIdeas.com is a global news source for investors following leading business sectors including biotech, tech, mining, mobile, energy, water, defense and security, renewable energy, food and beverage stocks and Latin American stocks.
Sign up for our free news alerts:
http://www.investorideas.com/Resources/Newsletter.asp
Become an Investorideas.com Member and use our online stock directories to research stocks - waters stocks, renewable energy, tech, mobile, mining stocks and more… http://www.investorideas.com/membership
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.aspBC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: Disclosure: NXTD and Tekcapital are clients of Investorideas.com .http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
Presenting Companies Contact info:
Cali V cvanzant@investorideas.com 800. 665. 0411
Sponsorship info:
Eric Salvarezza esalvarezza@investorideas.com 631. 664. 1311
Media Partners:
Dawn V dvanzant@investorideas.com 800. 665. 0411
800-665-0411 - Source: www.Investorideas.com

Disclaimer/ Disclosure:The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Biotech News Alert: SUNSHINE BIOPHARMA (OTCQB: SBFM) EXPANDS DRUG PIPELINE TARGETING PANCREATIC CANCER AS SECOND INDICATION FOR CLINICAL TRIALS OF Adva-27a COMPOUND

Montreal, Quebec, Canada - January 22, 2014 (Investorideas.com Biotech Newswire) Biopharma alert: Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, reports that it is targeting pancreatic cancer as a second indication for Adva-27a, the Company’s flagship anticancer drug candidate. As previously announced (see press release dated June 4, 2013), Adva-27a, a Topoisomerase II inhibitor, was found to be effective at destroying cells of the very aggressive pancreatic cancer cell line, Panc-1. Adva-27a was able to kill these cells with an IC50 of approximately 4 micromolar, a pharmacologically very favorable drug concentration. Based on initial data, the Company is moving forward with intentions to conduct a Phase I clinical trial of Adva-27a for pancreatic cancer in parallel to the planned Phase I clinical trial of Adva-27a for breast cancer that is scheduled to be hosted at McGill University's Jewish General Hospital in Montreal.

Full news: http://www.investorideas.com/CO/SBFM/news/2014/01211.asp
January 21 st Close : $0.20 Up 0.03(14.29%)
About Adva-27a
Adva-27a is Sunshine Biopharma's lead anticancer compound, a small molecule that has recently been shown to be effective at killing multidrug resistant breast cancer cells, small-cell lung cancer cells, uterine sarcoma cells and pancreatic cancer cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). Adva-27a is currently in the IND-Enabling stage of development. The original U.S. patent covering Adva-27a was issued on August 7, 2012 under U.S. patent number 8,236,935.
About Sunshine Biopharma Inc.
Sunshine Biopharma is an early stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. Sunshine Biopharma recently announced that it has initiated IND-Enabling studies for its lead antitumor compound, Adva-27a, which is currently targeted for multidrug resistant cancer.
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
For Additional Information Contact:
Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com
Disclaimer/ Disclosure:The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: SBFM has renewed effective December 3,2013 with Investorideas for six months of news publication and general public awareness of the company news and technologies and products in the biopharma markets ( one hundred thousand shares of 144 stock per 3 month period for a total of six months ) More disclaimer info: http://www.investorideas.com/About/Disclaimer.aspBC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Biometric Stock Alert: Mobile Biometric Company NXT-ID, Inc. (OTCQB: NXTD) to Team With the John F. Welch College of Business at Sacred Heart University

SHELTON, CT - January 21, 2014 (Investorideas.com Newswire) NXT-ID (OTCQB: NXTD), a biometrics company focused on the growing m-commerce market, announces it will be doing a joint project with students at the John F. Welch College of Business at Sacred Heart University in Fairfield, CT to assist with the marketing roll out of its next generation smart wallet, the Wocket™.

The Wocket™ is a new biometrically secure smart wallet designed to replace the traditional wallet and the number of cards consumers carry. Its dynamically programmable magnetic stripe, NXTCard can replace more than 100 cards and can include medical records, ID, coupons etc. that are currently kept in a wallet, with one single secure card.
In the initial phase of the project, students will research the market, the competition, and consumer trends related to the Wocket. The second part of the project will be primary research (surveys and focus groups) on the product, its features, possible marketing positioning and pricing and the final phase will be live on campus testing.
"We are delighted to be announcing this collaboration with the John F. Welch College of Business," said Mr. Gino Pereira, CEO of NXT-ID, Inc. "It is particularly relevant as one of our initial target group of customers for the Wocket are college students and campuses where there is a unique combination of open loop and closed loop payment systems combined with a particular need for security with access control to buildings."
"We are looking forward to working with Nxt-ID and their innovative technology," said Kwamie Dunbar, assistant professor of Finance at the John F. Welch College of Business. "This gives our students the type of real life hands on experience that the College prides itself on."
On January 25, 2006, Jack Welch, the former Chairman and CEO of General Electric, gave an endowment and his name to Sacred Heart University's College of Business, which is now known as the John F. Welch College of Business.
About the John F. Welsh College of Business
The John F. Welch College of Business at Sacred Heart emphasizes core business skills and knowledge, communications skills, and ethics. We stress hands on learning, understanding of the global marketplace, and state-of-the-art technology. The College enrolls over 950 students in undergraduate and graduate degree programs and the faculty consists of more than 40 professors, who are recognized scholars and experienced practitioners in the business world.
About NXT- ID Inc. - Mobile Security for a Mobile World
NXT-ID, Inc.'s (OTCQB: NXTD) innovative MobileBio™ solution mitigates consumer risks associated with mobile computing, m-commerce and smart OS-enabled devices. The company is focused on the growing m-commerce market, launching its innovative MobileBio™ suite of biometric solutions that secure consumers' mobile platforms led by the Wocket™, a next generation smart wallet designed to replace all the cards in your wallet, no smart phone required. The Wocket works anywhere credit cards are accepted and only works with your biometric stamp of approval. http://www.thewocket.com/
NXT-ID' wholly owned subsidiary, 3D-ID LLC, is engaged in biometric identification has 22 licensed patents in the field of 3D facial recognition http://www.nxt-id.com/, http://3d-id.net/
Forward-Looking Statements for NXT-ID
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company's reports filed with the Securities and Exchange Commission.
Contact:
Investor Inquiries:
Kirin Smith
ProActive Capital Group
Direct: 646 863 6519
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: November 2013 :Investorideas is compensated by NXTD: five thousand per month for news publication and syndication and is long 144 shares from previous services
More info: http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Biotech News Alert: Sunshine Biopharma (OTCQB: SBFM) Targets Pancreatic Cancer as Second Indication for Clinical Trials of Adva-27a Compound

MONTREAL, QC - January 21, 2014 (Investorideas.com Biotech Newswire) Sunshine Biopharma Inc. ( OTCQB: SBFM ), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it is now targeting pancreatic cancer as a second indication for Adva-27a, the Company's flagship anticancer drug candidate. As previously announced (see press release dated June 4, 2013), Adva-27a, a Topoisomerase II inhibitor, was found to be effective at destroying cells of the very aggressive pancreatic cancer cell line, Panc-1. Adva-27a was able to kill these cells with an IC50 of approximately 4 micromolar, a pharmacologically very favorable drug concentration. Based on initial data, the Company is moving forward with intentions to conduct a Phase I clinical trial of Adva-27a for pancreatic cancer in parallel to the planned Phase I clinical trial of Adva-27a for breast cancer that is scheduled to be hosted at McGill University's Jewish General Hospital in Montreal.

"As we work towards completing the process of re-domiciling the Company to Canada and conducting the requisite IND-enabling toxicology studies of Adva-27a, we are now proceeding with additional research centered on pancreatic cancer as a second indication," said Dr. Steve N. Slilaty, Chief Executive Officer of Sunshine Biopharma. "Pancreatic cancer represents an area of tremendous unmet medical need and significant market opportunity. Our research to date indicates that Adva-27a has the potential to become a new therapy option for patients suffering this deadly form of cancer."
About Pancreatic Cancer
Pancreatic cancer has an extremely poor prognosis. Most pancreatic cancer patients will die within one year of diagnosis. Cancer of the pancreas is the fourth most common cause of cancer-related deaths in the United States. According to the American Cancer Society, an estimated 45,220 new cases of pancreatic cancer will be diagnosed in the U.S. in 2013. Approximately 95% of pancreatic tumors are of the adenocarcinoma type, arising within the exocrine component of the pancreas where various digestive enzymes are produced. The remaining 5% arise from the islet cells and are classified as neuroendocrine tumors. The islet cells produce important hormones such as insulin, which regulates the sugar levels in the blood. Both types are very aggressive and respond poorly to standard chemotherapy drugs. In contrast to the downward trend in death rates for most major cancer types, death rates due to pancreatic cancer have been slowly increasing in the U.S. over the past decade. This, together with the lack effective therapy, underscores the need for major new drug development efforts to reverse these trends.
About Adva-27a
Adva-27a is Sunshine Biopharma's lead anticancer compound, a small molecule that has recently been shown to be effective at killing multidrug resistant breast cancer cells, small-cell lung cancer cells, uterine sarcoma cells and pancreatic cancer cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). Adva-27a is currently in the IND-Enabling stage of development. The original U.S. patent covering Adva-27a was issued on August 7, 2012 under U.S. patent number 8,236,935.
About Sunshine Biopharma Inc.
Sunshine Biopharma is an early stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. Sunshine Biopharma recently announced that it has initiated IND-Enabling studies for its lead antitumor compound, Adva-27a, which is currently targeted for multidrug resistant cancer.
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
For Additional Information Contact:
Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com
Disclaimer/ Disclosure:The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: SBFM has renewed effective December 3,2013 with Investorideas for six months of news publication and general public awareness of the company news and technologies and products in the biopharma markets ( one hundred thousand shares of 144 stock per 3 month period for a total of six months ) More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

TSX Biotech Stock: Q&A Interview with CEO of Quest PharmaTech (TSX.V: QPT)

New York NY - Point Roberts WA - January 21, 2014 (Investorideas.com Newswire) Investorideas.com, a global news source for leading sectors including biotech and pharma issues an exclusive interview with Dr. Madi R. Madiyalakan, Ph.D., Chief Executive Officer of Quest PharmaTech Inc. (TSX.V: QPT). Dr. Madiyalakan shares insight into the Company’s pipeline of oncology products. The Company takes a unique approach to cancer treatment that capitalizes on the recent major advances in the understanding of immune physiology and developing proprietary next generation cancer immunotherapy treatments using select antibodies, adjuvants and photosensitizers.

Interview:
Q: Investorideas.com
For readers unfamiliar with your company, can you give a brief introduction on your background in the biotech space and the formation of Quest PharmaTech?
A: Madi R. Madiyalakan, Ph.D., Chief Executive Officer
I have been involved in the Biotech industry for over 27 years, first as a scientist at Biomira Inc (now known as Oncothyreon) and then as a founding executive team member of several biotech companies including, AltaRex Corp., CanBiocin Inc. and SonoLight Pharmaceuticals Corp. My relationship with Quest began when Quest PharmaTech acquired SonoLight Pharmaceuticals in 2001. That acquisition provided a path forward for technology I had invented and championed ([Dr. Madiyalakan holds 10 primary U.S. patents and eight pending patents]). I have been instrumental in raising more than $200 million through private placement and public offerings for those companies. I specialize in advancing novel technologies with great therapeutic potential in areas of unmet medical need.
Quest was started as a research and development company in 1998 and was listed on the TSX Venture Exchange in 1999. I have been CEO of the Company since 2006.
Q: Investorideas.com
Can you briefly describe the current product portfolio and the primary oncology focus for each?
A: Madi R. Madiyalakan, Ph.D., Chief Executive Officer
Our technology is focused on the immunotherapy of cancer. We utilize tumor directed monoclonal antibodies to activate the specific immunity; however we recognize that successful therapy requires orchestrated combination with chemotherapy, photodynamic therapy and select additional immune modulators or adjuvants. Our lead product, Oregovomab, which is currently completing a phase II clinical trial in both Italy and the U.S., is used in combination with standard chemotherapy in ovarian cancer patients. It is also being tested in combination with other immunotherapeutic agents for use in treating pancreatic cancer patients. Our pipeline also includes proprietary antibodies against other cancer markers, most notably MUC1, PSA and HER2. We expect to advance our MUC1 targeting antibody into the clinic in the coming year. MUC1 expressing cancers include many commonly occurring solid cancers such as breast, pancreatic and lung cancers.
We are also very excited about our new pipeline of therapeutic IgE antibodies, which we recently acquired from Advanced Immune Therapeutics, Inc. and for which we obtained license rights from UCLA and Stanford University. In addition to their immunotherapeutic potential, these molecules also have the potential to act in the tumor micro-environment to augment the effectiveness of chemotherapy. We truly believe that the IgE technology will be a breakthrough for the treatment of cancer.
Q: Investorideas.com
Can you discuss the current status of your flagship product OREGOVOMAB and its applications in immune therapy?
A: Madi R. Madiyalakan, Ph.D., Chief Executive Officer
Quest's proprietary approach uses antibodies to modulate and enhance specific immunity to the target tumor antigen and associated tumor. Recent insights into the ability of cytotoxic therapy to enhance immunity, and the development of novel adjuvant approaches, suggests that a simple and artful approach using a combination of components for specific cancer immunotherapy can change the clinical course of cancer. We are using our lead product Oregovomab as an example to demonstrate the proof of concept for the combinatorial immunotherapeutic approach and trying to identify ideal combinations by conducting three different clinical trials. The most advanced of these is an 80 patient phase II clinical trial in advanced ovarian cancer patients that is being conducted in 13 clinical centers in Italy and the U.S. We hope the results from this trial will confirm the findings in an earlier study that shows combining chemotherapy with Oregovomab leads to the generation of specific anti-cancer T-cells and the potential for clinical benefits. We are also conducting another clinical trial in the U.S. using Oregovomab in combination with another chemotherapeutic agent, Gemcitabine, together with radiation therapy for treating pancreatic cancer. The trial will help us to expand the market opportunities for Oregovomab to other CA125 expressing cancers as well as to evaluate immunotherapy in combination with chemo radiotherapy. We are also looking at the addition of an immunoadjuvant, Hiltonol, a TLR3 agonist, which we have licensed from a U.S based company, Oncovir, to further augment the immune response. The completion of these 3 clinical trials will provide us with the roadmap for commercialization of this product. To summarize, Quest's approach has created an opportunity to mobilize immunity, better, more precisely and for less cost than other methods that are in development, and, or, recently approved.
Q: Investorideas.com
Can you give us some background on the key members of your team and the scientific board and the expertise they bring to the company?
A: Madi R. Madiyalakan, Ph.D., Chief Executive Officer
Working with me on themanagement team, I have Thomas Woo, Vice President of Product Development since 2002. Thomas honed his drug development skills at Biomira, AltaRex and Cytovax. My CFO, Pierre Vermette, comes with extensive experience gained at the Alberta Securities Commission and has been with the Company since 2003.
On theBoard of Directors, I have Lorne Meikle, our Chairman, Ian McConnan, our Audit Committee Chair and Paul Van Damme, our Corporate Governance Chair.
Mr. Meikle has an extensive background in the life sciences area, Mr. McConnan is a former partner of several public accounting firms, and Mr. Van Damme has acted in the CFO role for a number of public and private companies.
On the Company's Scientific Advisory Board, I have internationally known scientists who occupy important positions in various institutions around the world. Dr. Samuel Abraham, Ph.D., is the Vice President of Research with the British Columbia Cancer Agency. Professor Ki-Jun Hwang is a well respected medicinal chemist at Chonbuk University in South Korea. One of the clinicians, Dr. Ronald Moore, who is developing a unique treatment for prostate cancer at the Cross Cancer Institute in Canada, is also one of our scientific advisory board members. Dr. Moore, along with Dr. Gerald Miller in Australia, provide a strong scientific direction to our photodynamic therapy program.
On the Company's Clinical Advisory Board (CAB), I have Dr. Christopher Nicodemus, a clinical expert in tumor immunology and drug development who has been championing the combinatorial immunotherapeutic approach supported by numerous publications and patents. He relies on the advice of his fellow CAB members, key opinion leaders such as Professor William McGuire in the U.S, Professor Ignace Vergote in Belgium and Dr. Thomas Ehlen in Canada.
All members of the CAB have a keen interest in innovative improvements in the area of ovarian cancer and see a great opportunity to advance the previous learning with Oregovomab in the context of combination therapies that will better access the immune response and limit immune suppression that has impeded earlier efforts to vaccinate against cancer.
Q: Investorideas.com
Can you share with readers the significance of some of your key relationships including Stanford University and UCLA?
A: Madi R. Madiyalakan, Ph.D., Chief Executive Officer
Significance of Key Relationships:
We are very pleased to be licensing IgE technologies developed by the distinguished scientists from these prestigious institutions. In addition, we are also working closely with the Eppley Cancer Institute at the University of Nebraska to develop animal models and complete pre-clinical testing of potential drug candidates.
Q: Investorideas.com
With all biotech companies, funding is a key factor to success; last November you announced a $1million placement for Quest PharmaTech. C an you explain the significance of this round of financing and where this takes you to?
A: Madi R. Madiyalakan, Ph.D., Chief Executive Officer
We wanted to strengthen our relationship with our long term investment partner, AD Biotech Co., Ltd. AD Biotech has committed $12 Million to fund our ongoing clinical programs during the next two years. We were pleased with their confidence in Quest as demonstrated by their investment of $1 Million at a premium share price.
Q: Investorideas.com
In closing what are some of the key milestones for 2014 for Quest PharmaTech?
A: Madi R. Madiyalakan, Ph.D., Chief Executive Officer
Some of the key 2014 milestones we hope to achieve in the coming year include completing patient enrollment of the Oregovomab clinical trial and obtaining preliminary data for the Oregovomab clinical trial in Italy and US; initiating a clinical study combining Oregovomab with immuno-adjuvants; expanding the Company's opportunities for revenue generation through product sales of some evidence based over-the-counter nutraceutical and cosmetic products licensed from our joint venture partner; generating critical additional data demonstrating the therapeutic potential of our proprietary IgE portfolio; and, pursuing out-licensing arrangements as a source of additional revenue and validation for our technologies.
About Quest PharmaTech Inc.:
Quest PharmaTech Inc. (Quest) is a publicly traded (TSX Venture), Alberta-based biotechnology company committed to the development and commercialization of oncology product candidates. It is developing a series of products for the treatment of cancer based on its pipeline of SonoLight compounds, and monoclonal antibodies that target certain tumor antigens that are presented in a variety of cancers. Quest believes that by combining these antibodies with other cancer therapies such as chemotherapy or photodynamic therapy, it can potentially further complement and enhance treatment outcomes compared to antibody treatment alone. http://www.questpharmatech.com/
About InvestorIdeas.com:
InvestorIdeas.com is a global news source for investors following leading business sectors including biotech, tech, mining, mobile, energy, water, defense and security, renewable energy and Latin American stocks.
Sign up for our free news alerts
http://www.investorideas.com/Resources/Newsletter.asp
Become an Investorideas.com Member http://www.investorideas.com/membership/
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: QPT.V, a public company, has engaged Investorideas.com for public relations services for four thousand a month retainer fee.
More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Global investors must adhere to regulations of each country.
800-665-0411 - Source - www.Investorideas.com

Biopharma Q&A Interview; Dr. Steve N. Slilaty Ph.D., Chairman, CEO of Sunshine Biopharma (OTCQB: SBFM) Shares Insight into Recent Company Move and Updates Lead Cancer Compound Adva-27a

New York, NY, Point Roberts, WA - December 19, 2013 (Investorideas.com Biotech Newswire) Investorideas.com, a research and news portal covering leading sectors, issues an exclusive Q&A interview with Dr. Steve N. Slilaty Ph.D., Chairman and CEO of Sunshine Biopharma Inc. (OTCQB: SBFM). Sunshine is Biopharma a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer.

Dr. Steve N. Slilaty shares insight to the recent news that it has re-domiciled in Canada for expansion through acquisitions and to gain access to various financing opportunities available to Canadian corporations, in addition to updating the current status of its lead cancer product Adva-27a.
Q: Investorideas.com
Dr. Slilaty can you explain to investors the significance of the recent move to Canada corporately and what direct benefits are realized?
A: Dr. Steve N. Slilaty Ph.D., Chairman, CEO
There are several advantages relating to the fiscal environment in Canada which are conducive to companies planning to expand through acquisitions. For example, there are provisions in the Canadian Tax Act which allow Canadian companies to acquire other Canadian companies in a share exchange transaction on a tax exempt basis. In addition, there are significant tax credits available to Canadian companies conducting R&D in Canada and Sunshine’s drug development program would benefit a great deal such tax provisions.
Q: Investorideas.com
For investors unfamiliar with your company, can you give a brief history of some of the data and testing on your lead compound Adva-27a and the basic principle of how it works?
A: Dr. Steve N. Slilaty Ph.D., Chairman, CEO
Adva-27a is Topoisomerase 2 inhibitor. Suppression of Topoisomerase 2 enzyme activity is a well-established anticancer target. Unlike all existing Topoisomerase 2 inhibitors, Adva-27a continues to work even when cells become multidrug resistant. This remarkable property is unique to Adva-27a! Our preclinical studies to date have shown that:

• Adva-27a is effective at killing different types of multidrug resistant cancer cells, including:
• Breast Cancer Cells (MCF-7/MDR)
• Small-Cell Lung Cancer Cells (H69AR)
• Uterine Cancer (MES-SA/Dx5)
• Pancreatic Cancer (Panc-1)
• Adva-27a is unaffected by P-Glycoprotein, the enzyme responsible for making cancer cells resistant to anti-tumor drugs
• Adva-27a has excellent clearance time (half-life = 54 minutes) as indicated by human microsomes stability studies and pharmacokinetics data in rats
• Adva-27a clearance is independent of Cytochrome P450, a mechanism that is less likely to produce toxic intermediates
• Adva-27a is an excellent inhibitor of Topoisomerase II with an IC50 of only 13.7 micromolar
• Adva-27a has shown excellent pharmacokinetics profile as indicated by studies done in rats
• Adva-27a does not inhibit tubulin assembly
• Adva-27a exhibits low toxicity levels as indicated by measurements using the non-cancerous cell line, HMEC

Q: Investorideas.com
With data on multiple cancers, is there one area the company will focus on specifically?
A: Dr. Steve N. Slilaty Ph.D., Chairman, CEO
Yes, we are initially focused on treating breast cancer patients whose disease has become multidrug resistant. These patients currently have no treatment options available to them as all existing anticancer drugs cease to work. We are anxious to make our Adva-27a available to them soon. To this end, we have signed an agreement with McGill University’s Jewish General Hospital here in Montreal ( Canada) to conduct Phase I clinical trials on such patients. This is the first step in our clinical development program of Adva-27a.
Q: Investorideas.com
For investors unfamiliar with the difference between getting approval in Canada vs. US FDA approval, can you explain the process in Canada, the timelines, cost and what is next for Sunshine Biopharma?
A: Dr. Steve N. Slilaty Ph.D., Chairman, CEO
The approval process in Canada is very similar to that of the United States. Health Canada has very similar guidelines to those established by the FDA in the U.S. In fact, our Phase I clinical trials protocols are compliant with the requirements on both sides of the boarder and we will be able to file our results both in Canada and the US pretty much simultaneously. In terms of timelines, like the U.S., Canada has a so-called “fast-track” process for which is available for drugs that treat terminally ill patients as is the case with Adva-27a. Next, we anticipate initiating the human trials following completion of our next round of financing.
About Adva-27a
Adva-27a is Sunshine Biopharma's lead anticancer compound, a small molecule that has recently been shown to be effective at killing multidrug resistant breast cancer cells, small-cell lung cancer cells, uterine sarcoma cells and pancreatic cancer cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). Adva-27a is currently in the IND-Enabling stage of development. The original U.S. patent covering Adva-27a was issued on August 7, 2012 under US patent number 8,236,935.
About Sunshine Biopharma Inc. (OTCQB: SBFM):
Sunshine Biopharma is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company's lead compound, Adva-27a targets aggressive forms of cancer www.sunshinebiopharma.com
Recent news: http://finance.yahoo.com/news/sunshine-biopharma-domicile-canada-expansion-130000999.html
About InvestorIdeas.com:
InvestorIdeas.com is a global news source for investors following leading business sectors including biotech, tech, mining, mobile, energy, water, defense and security, renewable energy, food and beverage stocks and Latin American stocks.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for our free news alerts
http://www.investorideas.com/Resources/Newsletter.asp
Become an Investorideas.com Member and use our online stock directories to research stocks - waters stocks, renewable energy, tech, mobile, mining stocks and more… http://www.investorideas.com/membership/
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: SBFM compensates Investorideas for news publication and distribution (one hundred thousand 144 shares in lieu of cash for a six month period) more disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
800-665-0411 -   Source - www.Investorideas.com